Summit Therapeutics Inc (SMMT) USD0.01
Summit Therapeutics Inc. is focused on developing treatments for infectious diseases. The Company uses its Discuva platform, an antibiotic discovery engine to develop antibiotics. It is initially focused on Clostridioides difficile infections (CDI). Its platform is designed to uncover novel bacterial targets and develops new mechanism antibiotics against them. Ridinilazole is its new mechanism antibiotic, which is being developed for CDI.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.